As of September 18, 2026, ABBOTINDIA's technical stance is mixed, with a daily uptrend conflicting with longer-term bearish signals. The stock's closing price of ₹27,270.0 is above key daily moving averages, including the 20-day EMA (₹26,210.11) and 200-day SMA (₹26,992.05), indicating positive short-term momentum. However, on a weekly and monthly basis, the price is below the Supertrend indicator and key moving averages, suggesting underlying weakness. The nearest support is observed at ₹26,826.56, approximately 1.63% below the current price, while the nearest resistance is at ₹28,521.55, about 4.59% higher. Recent activity includes a "Morning Star" pattern on the daily chart and a "Harami" pattern on the monthly chart, both potentially signaling trend reversals. The stock has experienced significant volume with price movement on September 18, 2026, with a volume ratio of 5.07 and a Z-score of 13.9.

The stock's current position is within the upper half of its 50-day and 252-day trading ranges, with the 50-day range position at 0.56 and the 252-day range position at 0.34. Annualized volatility stands at 23%, and the current drawdown is -24%. The conflicting signals across timeframes suggest a period of consolidation or transition. Key watch conditions include monitoring the price action around the ₹26,826.56 support level and the ₹28,521.55 resistance level. A decisive break above resistance could strengthen the daily uptrend, while a fall below support might signal further downside, especially if it coincides with increased selling volume.

Abbott India Ltd's stock experienced a third consecutive day of gains, closing at ₹26,155 on September 15, 2026, marking a 2.37% increase for that day. Despite this recent upward trend, the stock has seen a 15.44% decline over the past year. This performance contrasts with the broader market, as the NIFTY index rose 7.58% and the Nifty Pharma index increased by 18.39% during the same one-year period. Separately, a report on September 14, 2026, highlighted intensifying regulatory scrutiny in India's Fast-Moving Consumer Goods (FMCG) sector concerning misleading product claims. This regulatory push, which includes proposed front-of-pack warning labels for unhealthy packaged foods, is prompting companies to increase investments in compliance and quality checks.

As of September 18, 2026, Abbott India's stock has seen an increase in price. The previous price recorded was ₹25,910.0, and the current price is ₹27,270.0. No new filings or news developments were reported for the period.

The company, commonly known as Abbott India, continues to be listed on the NSE. The recent price movement represents a change from the prior recorded price, while other contextual elements remain consistent.

Abbott India's financial position shows a notable increase in total assets from ₹2,941 crore in March 2019 to ₹3,547 crore in March 2020. This growth is primarily driven by a significant rise in fixed assets, which increased from ₹105 crore to ₹270 crore over the same period, alongside an increase in other assets. Concurrently, total liabilities also grew, with borrowings appearing in March 2020 at ₹175 crore, compared to none in March 2019. The company's reserves saw a substantial increase from ₹1,987 crore to ₹2,410 crore between March 2019 and March 2020. Cash flow from operating activities increased to ₹626 crore in March 2020 from ₹499 crore in March 2019, contributing to a higher free cash flow of ₹611 crore in March 2020. However, net cash flow decreased to ₹8 crore in March 2020 from ₹99 crore in March 2019, impacted by increased cash used in investing activities, which rose to ₹401 crore from ₹257 crore.

In terms of market performance, Abbott India's stock has experienced a decline of 15.44% over the past year, contrasting with the Nifty's 7.58% jump and the Nifty Pharma index's 18.39% rise. Recent news indicates the stock has risen for three consecutive sessions, trading at ₹26,155 as of 12:49 IST on the NSE. Separately, a broader market development highlights increasing regulatory scrutiny on Indian FMCG brands regarding product claims, with proposed front-of-pack warning labels for unhealthy foods, prompting companies to allocate more resources to compliance and quality checks.

Abbott India's recent financial performance shows a consistent upward trend in sales and profitability. For the fiscal year ending March 2024, sales reached ₹5,849 crore, with operating profit at ₹1,453 crore and a net profit of ₹1,201 crore. The operating profit margin (OPM) stood at 25.0% for the same period. Looking ahead, projections indicate continued growth, with estimated sales of ₹6,409 crore for FY25 and ₹6,929 crore for FY26, accompanied by expanding OPM to 26.0% and 27.0% respectively. Earnings per share (EPS) have also shown a strong trajectory, growing from ₹211.93 in FY19 to ₹565.30 in FY24, with further increases projected to ₹665.64 in FY25 and ₹730.39 in FY26.

The company's balance sheet indicates a reduction in borrowings, which decreased from ₹175 crore in March 2020 to ₹83 crore in March 2024. Equity capital has remained stable at ₹21 crore throughout this period, while reserves have grown significantly from ₹2,410 crore in March 2020 to ₹3,678 crore in March 2024. This suggests a strengthening financial position with decreasing reliance on debt. Cash flow from operations has been robust, with ₹1,213 crore generated in FY24, contributing to a healthy free cash flow of ₹1,165 crore in the same year. Key monitoring areas include the increasing trend in Other Assets, which rose from ₹3,275 crore in March 2020 to ₹4,958 crore in March 2024, and the fluctuating Cash from Investing Activity, which saw a significant outflow of ₹416 crore in FY24.

Abbott India's financial performance shows positive trends in cash flow generation and profit growth. The company has demonstrated a consistent increase in its reserves, growing from ₹2,410 crore in March 2020 to ₹1,987 crore in March 2019. Furthermore, its operating cash flow has seen an increase, with Free Cash Flow rising to ₹611 crore in March 2020 from ₹504 crore in March 2019. The company has also achieved a compounded profit growth of 17% over the last five years and 11% on a trailing twelve-month (TTM) basis. While the company has seen an increase in borrowings from ₹0 crore in March 2019 to ₹175 crore in March 2020, its equity capital has remained stable at ₹21 crore, and its reserves have grown significantly.

Abbott India's financial position shows an increase in borrowings from ₹0 in March 2019 to ₹175 crore in March 2020. Concurrently, fixed assets have more than doubled from ₹105 crore to ₹270 crore over the same period. While cash flow from operations increased to ₹626 crore in March 2020 from ₹499 crore in March 2019, cash used in investing activities also rose significantly to ₹401 crore from ₹257 crore. The company's net cash flow declined to ₹8 crore in March 2020 from ₹99 crore in the prior year. In terms of market performance, the stock has seen a decline of 15.44% over the last year, underperforming the Nifty Pharma index which jumped 18.39% and the Nifty which rose 7.58% in the same timeframe.